Potent and selective NMDA antagonist that acts through the glycine site (IC50
= 5 nM). Displays > 500-fold selectivity over kainate and AMPA receptors (IC50
values are 2.7 and 3 μ
M respectively). Anticonvulsant in vivo
following systemic administration. Also available as part of the NMDA Receptor - Glycine Site Tocriset™
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of Novartis Pharma AG
Synthesis, radiolabelling and biological characterization of (D)-7-iodo-N-(1-phosphonoethyl)l-5-aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors.
Ametamey et al.
N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists.
Auberson et al.
Synthesis and characterisation of [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new σ receptor radiopharmaceutical: high affinity binding to MCF-7 breast tumor cells.
John et al.
Antagonistm of N-methyl-D-aspartate receptors by σ site ligands: potency, subtype-selectivity and mechanisms of inhibition.
Whittemore et al.